作者: Mary Rose Masikat , Qi Cai , Alexander R. Steiner , Aaron K. Sato , Trevor J. Hallam
关键词:
摘要: Antibody drug conjugates (ADCs) harness the target specificity of a monoclonal antibody (mAb) and high cytotoxicity small molecule, enabling improved delivery potent antitumor agent compared to traditional chemotherapy for cancer therapy. Only two ADCs have been marketed, both which are produced via nonsite-specific conjugation cytotoxic either interchain cysteine (Adcetris) or lysine (Kadcyla). A growing body evidence suggests that site-specific ADCs, because their payload homogeneity, will improve pharmacokinetics wider therapeutic windows when heterogeneous ADCs. Previously, we demonstrated use cell free expression system (Xpress CF+) rapid production Here report generation variety between incorporated non-natural amino acid (nnAA), para-azidomethyl-l-phenylalanine (pAMF), dibenzocyclooctyl-(polyethylene glycol)4 (DBCO-(PEG)4) linked payloads using ...